Twelve Months 2020 Moberg Pharma AB (publ) Earnings Call Transcript
Hello, and welcome to the Moberg Pharma conference call. (Operator Instructions) Just to remind you, this call is being recorded. Today, I'm pleased to present Anna Ljung. Please begin your meeting.
()-
Thank you. Hello, everyone. My name is Anna Ljung, and I'm the CEO of Moberg Pharma. I also have our VP of Finance, Mark Beveridge with me here today. And I'm happy to present our interim report covering this last quarter, April to June. And you can find the report on our web page. And there, you can also find a PowerPoint presentation that I will use in this telephone meeting.
So I will start on Page 4 in that presentation, with a brief summary. So we're a Swedish pharmaceutical company that base our products on drug delivery of known substances, which reduces time to market and development risk compared to traditional drug development. We have a clinical pipeline consisting of 2 late-stage drug candidates, MOB-015 and BUPI, both of which have demonstrated strong clinical results,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |